Women still not being told about pregnancy risks of valproate
BMJ 2017; 358 doi: https://doi.org/10.1136/bmj.j4426 (Published 22 September 2017) Cite this as: BMJ 2017;358:j4426- Jacqui Wise
- London
Two thirds of women who take the antiepileptic drug sodium valproate said they had not received new safety warnings about the dangers of taking it during pregnancy, a survey carried out by epilepsy charities has found. A similar survey last year found that half of women taking the drug were unaware it could harm their fetus.1
The new results are to be presented at a public hearing on the safety of valproate drugs organised by the European Medicines Agency on 26 September in London. This is the first time that the EMA has held a public hearing as part of the safety review of a drug, and it will …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.